A new case series in Frontiers in Pharmacology is going to circulate widely in psychedelic circles. Three people with lasting symptoms after a brain injury went through a six-week iboga microdosing protocol paired with therapy. Two improved and held those gains. One had less impressive gains, but still improved despite adverse events in their life.
Before this paper get flattened into “iboga heals brain injury,” it helps to read what the paper actually says. The authors are careful.
Since there are special risks with Iboga, we should be too.
What the study did
Burton Tabaac, Robin Carhart-Harris, and Teresa Yung followed three patients through a participant-directed protocol using whole Tabernanthe Iboga root bark. Not isolated ibogaine, which is the drug most clinics use. Lab testing put the material at about 3.8% ibogaine by mass.
Patients dosed four days on, three days off, for six weeks. The daily amount ran from 0.1 to 1.0 grams of root bark, which the authors estimate at 3.8 to 38.5 mg of ibogaine-equivalent. Each met weekly for Accelerated Experiential Dynamic Psychotherapy (AEDP), a body-focused, relationship-centered approach. Supplements and lifestyle changes were also part of the protocol.
The three patients were a 43-year-old man with post-concussive symptoms after a motorcycle crash; a 40-year-old woman with seven years of headaches and brain fog after oxygen loss during an avalanche burial; and a 19-year-old woman with post-concussive symptoms after a car crash.
What happened
The first two did great, though the paper is careful to grade them differently. The man’s case it calls substantial improvement. He went from multiple daily anger outbursts and near-daily headaches to no outbursts and headaches every few months. He came off all his medications. He described himself as “better than ever, and better than before the accident.”
The 40 year old woman is the person the paper declares having complete symptom resolution. She stopped an antidepressant she had taken for twenty years. Her brain fog cleared. She said she felt like she was “living back in her own brain.” Both held their gains at long-term follow-up.
A timeline note matters here. This patient had also used psilocybin and LSD on her own, starting in 2021, and she credited LSD with part of her cognitive recovery. That use ran years before the iboga protocol began in late 2024, and she did not take either during the active treatment weeks. So it is not a case of mixing drugs in the moment. It is a reminder that she arrived with a psychedelic history the paper says shaped her baseline.
The third patient is perhaps the most interesting case. She sourced her own iboga and followed a protocol like her father’s, who had used it for his own TBI. And for a while, she improved a lot. She went from describing herself as “feeling drunk 90% of the time” to about 45% symptomatic. Her emotional volatility dropped by roughly 70%, a change her father confirmed. Nausea, vertigo, and hand numbness resolved completely. Headaches fell from several a week to one self-resolving episode in a month. Then, at her June follow-up, headaches, mood swings and cognitive fatigue came back . The authors say so directly, noting her path “may partially reflect the expected natural recovery curve” of mild TBI.
What the case series can’t show
This is simply a case series. It covers the experience of three people. It helps raise questions and can’t be seen as proof that iboga caused anything. Too many things were happening at once to credit any single one, not to mention the small sample size.
It was never iboga alone. The protocol paired the plant material with six weeks of Accelerated Experiential Dynamic Psychotherapy, a structured somatic approach that does real therapeutic work on its own. AEDP is not a background variable here. It is a core part of the treatment, which is exactly the problem for anyone trying to credit the iboga. When a serious psychotherapy, a ritualistic frame, supplements, and a strong expectation of getting better all run at once, you cannot clearly see what the plant is responsible for. The second patient’s earlier psychedelic history similarly reflects how messy real world case studies can be.
This shouldn’t undercut the value. We suspect that this case series is tremendously important.
Most concussion symptoms fade on their own. Even long-running cases can improve without treatment. The 19-year-old was three months out from her injury when starting microdosing which is well inside the window where people often get better. The two strong responders had carried their symptoms for years, and standard care had not moved them. That contrast is an essential part of the story.
A word about the dose
“Microdosing protocol” suggests something very specific, which is not the case. The daily range spanned a full order of magnitude, from about 3.8 to 38.5 mg of ibogaine-equivalent, and patients largely chose their own dose inside it. One person’s “microdose” could have been ten times another’s.
That range deserves attention, because dose is where iboga’s risk lives. Ibogaine can stretch the heart’s electrical cycle, called the QT interval. This can happe in a way that can trigger fatal heart rhythms, and the danger climbs with the amount in the body. The authors screened for heart problems and dangerous drug interactions, which is generally recognized as essential when working with this plant and it’s most famous molecule.
A tenfold, self-directed spread on dose is hard to study and harder to reproduce. Two people following “the same protocol” may not be running the same experiment. I personally find merit in the approach, given my experience, but understand why some might want more dose specific research, which I hope we’ll see sooner than later.
It also muddies the comparison to the veterans that the late Nolan Williams at Stanford studied, who each got a single weight-based flood dose under medical monitoring. The authors know this dose problem is substantial and list standardized dosing as a top priority for future work.
To counterpoint to all this caution, at Psychedelics Today, we have not seen a single report of a serious cardiac event from an iboga microdosing protocol. This is obviously not proof of safety. We might just not be hearing about it. Microdosing happens quietly, outside any system that would track a problem.
Ibogaine’s cardiac risk seems to rise with the amount in your body. A few milligrams a day is not the same load as a single flood dose, so it stands to reason the heart risk is lower. Lower risk is not no risk, which is why the screening in this paper still matters.
How it fits the larger iboga picture
Many readers will think of the Stanford work in veterans with traumatic brain injury. That study used a single high “flood” dose of magnesium-ibogaine and reported large drops in PTSD, depression, and disability. A later imaging paper from the same group went into new territory by using brain scans before and after treatment. The researchers found lasting increases in blood flow across the cortex and deeper brain regions, plus reorganized connections across brain networks. The blood-flow gains in the left insula and anterior cingulate (different parts of the human brain) tracked with reduced disability. Reduced blood flow is a known signature of brain injury, so this showed measured repair, not just symptom relief.
The two studies are near mirror images. Flood dose against microdose. A research clinic against a self-directed outpatient protocol. Pure molecule plus-magnesium against whole root bark. These papers come at the same question from opposite ends of the dosing range which makes the case series worth deeply considering.
Almost all the serious iboga science to date has used a single high dose, given once. This series asks a different question: what happens if you give small repeated doses over weeks, alongside structured therapy? We still don’t know the answer, and three uncontrolled cases do not provide it. But the question is a legitimate one, and it is new a newish and edgy conversation happening in psychedelic circles, at least in the USA. A weak study can still point at a good hypothesis. The value here is the study design ideas the patient outcomes are suggesting.
What might be driving it
The authors offer a possible mechanism and hold it loosely. The lead idea is neuroplasticity. In rodents, ibogaine raises growth factors like GDNF and BDNF in brain circuits tied to repair, and the thought is that a sustained microdosing window might push a brain with a stall in repair to remodel, with therapy shaping where that growth goes. They also note that a concussion’s mechanical shearing and an injury from oxygen loss are different harms that may still meet downstream in the same inflammation and plasticity pathways.
The authors measured none of this in these three patients. No growth factors tested, probably because this is hard to test in humans. No imaging of repair, which is quite expensive.
They call extending the rodent and addiction research to chronic brain injury “highly preliminary.” It is a story offered as a reason to run better studies, not a result.
The sourcing question
The paper does something most iboga research skips. It names its source: a family in the Congo, harvested through traditional practice.
That matters, because the wider iboga trade has a dark side. By most accounts, the large majority of iboga and ibogaine used outside Africa comes from plants poached in Gabon and moved out through Cameroon. INTERPOL reports that the same organized networks running ivory now traffic iboga, clearing protected forest as they go. Gabon treats iboga as a strategic resource and has moved to limit exports. High prices and online demand keep the illegal trade going.
If microdosing protocols like this one catch on, demand grows with them. Interest in iboga’s promise has to carry the sourcing question alongside it. Not as a footnote. As part of the same conversation.
A more bullish reading
Not everyone reads the paper as cautiously as its authors wrote it. Court Wing, of REMAP Therapeutics and the Psychedelics and Pain Association, calls it a demarcation line. A possible turning point not just for traumatic brain injury and post-concussion syndrome, but maybe for stroke and other brain conditions down the line.
His argument is worth hearing in full. Look at the actual exams, he says. The patients’ standard neurological workups came back normal. Their function tests and psychological evaluations look, to him, like remission. In his reading, the reason the authors stop short of saying “recovered” or “in remission” is not that the people aren’t. It is that academics writing a case series structurally cannot make that claim. “No clinician looking at their psychological evaluations and function tests would claim that they are not in remission,” he says. All three described what felt to them like full recovery, and the people closest to them agreed.
On patient three, Court reads the “relapse” differently than the paper does. He puts her slide back at the point her microdosing stopped, after her sixth session, and notes she asked to do another round. To him, that says she needed a longer course and a deeper integration period, not that the approach failed.
And he points at what he sees as the real opportunity: pairing iboga microdosing with other forms of neurorehabilitation, not just psychotherapy. Prime the nervous system for a few weeks before or during the dosing, he argues, and the effects could compound. This is the way psilocybin paired with mirror-box therapy has amplified results for phantom-limb pain, a condition with a heavy cortical and structural-plasticity component.
Here is where I would mark the line. Court may be right, and his neurorehab-pairing idea is one of the more interesting hypotheses to come out of this paper. But his reading of patient three—iboga worked, then wore off—is one explanation. The paper offers another in the same breath: she may have been recovering and fluctuating on her own, the way mild TBI often does. Both fit the facts we have. The optimistic story and the natural-recovery story are still standing in the same room, and we need more data to tell them apart.
What to do with this
Not call it proof that iboga heals brain injury. The evidence here cannot carry that, and the authors would say so first. What it can support is smaller and more useful. This is a strong enough signal to justify some research in humans.
We need more carefully documented cases, small pilot studies with real controls, standardized measures, plasticity biomarkers, and follow-up long enough to separate drug effects from natural recovery and expectation.
Three substantial cases, in a screened, multimodal, honestly reported series, is a reason to lean in.
Lets get to work and make this research happen.
